The Mount Sinai Tisch Cancer Center (TCC) has launched a new AI-powered platform called PRISM to improve connections between cancer patients and suitable clinical trials.
Announced on January 8, 2026, PRISM was developed in partnership with AI company Triomics and is powered by OncoLLM, an oncology-specific large language model designed for cancer care. The platform analyzes electronic health records (from systems like Epic), including patient medical histories, diagnoses, and clinical details, to automatically identify eligibility for trials—replacing slow manual reviews with faster, systemwide screening.
This makes Mount Sinai the first NCI-designated Comprehensive Cancer Center in New York City to deploy such an oncology-focused AI tool across its entire health system, covering multiple hospitals and outpatient sites. For the full official announcement, see the Mount Sinai news release.
Key goals include:
- Expanding access to potentially life-saving trials
- Accelerating enrollment
- Identifying opportunities earlier in patient care
- Addressing awareness gaps, as many patients and physicians miss trial options
By automating matching, PRISM aims to boost participation, promote equity (especially for underrepresented groups), and advance cancer research more efficiently. Coverage in outlets like Medical News Today and Becker’s Hospital Review highlights its potential to transform trial access.
Additional details on Triomics’ technology are available on their site: How OncoLLM Works.
This launch highlights growing AI integration in oncology to bridge gaps between patients and innovative treatments. For more on Mount Sinai’s cancer care, visit their Tisch Cancer Center page.
MBH/AB